...
首页> 外文期刊>Current Pharmaceutical Biotechnology >Brain Delivery Systems via Mechanism Independent of Receptor-Mediated Endocytosis and Adsorptive-Mediated Endocv tosis
【24h】

Brain Delivery Systems via Mechanism Independent of Receptor-Mediated Endocytosis and Adsorptive-Mediated Endocv tosis

机译:通过独立于受体介导的内吞作用和吸附介导的内吞作用的机制的脑传递系统

获取原文
获取原文并翻译 | 示例
           

摘要

The endothelial cells of the brain form the blood-brain barrier (BBB) that denotes a major restraint for drug entry to the brain. Traditional attempts to bypass the BBB have been by formulation of drugs with lipophilicity or low molecular weight designed to enable transport via solute nutrient transporters. The identification of many new targets in the brain cells form new ways of thinking drug design as modern therapeutics could be proteins and molecules of genetic origins like siRNA and cDNA that are prevented from entry into the brain unless encapsulated in drug carriers. In many chronic disorders affecting the central nervous system, the BBB is physically intact which further limits the entry of large molecules. The desirable entry of such molecules will be made by formulation of particular drug carriers that will enable their transport into the brain endothelium, or even through the endothelium and into the brain. This review discusses the potential of different principles for drug therapy to the brain with these main emphases on drug transport through the BBB: ⅰ) the effects of molecular lipidization, ⅱ) the involvement of solute nutrient carriers, ⅲ) targeted delivery using small peptides with high membrane penetrating properties, ⅳ) treatment with magnetic nanoparticles. These different principles for therapy are also discussed with focus on possibilities of their improvement for targeted delivery to the brain.
机译:脑的内皮细胞形成血脑屏障(BBB),这是药物进入脑的主要限制。绕过血脑屏障的传统尝试是通过配制具有亲脂性或低分子量的药物来设计,以实现通过溶质营养转运蛋白的转运。鉴定脑细胞中许多新靶点构成了思考药物设计的新方法,因为现代治疗方法可能是蛋白质和遗传来源的分子,如siRNA和cDNA,除非包裹在药物载体中,否则它们无法进入大脑。在许多影响中枢神经系统的慢性疾病中,血脑屏障在身体上是完整的,这进一步限制了大分子的进入。这类分子的理想进入将通过配制特定的药物载体来实现,所述药物载体将使它们能够运输到大脑内皮中,甚至通过内皮运输到大脑中。这篇综述讨论了针对脑部药物治疗的不同原理的潜力,这些主要重点在于通过BBB进行药物运输:ⅰ)分子脂质化的影响,ⅱ)溶质营养载体的参与,ⅲ)使用小肽靶向递送高的膜穿透性能,ⅳ)用磁性纳米粒子处理。还讨论了这些不同的治疗原则,重点是改善其针对脑部靶向输送的可能性。

著录项

  • 来源
    《Current Pharmaceutical Biotechnology》 |2012年第12期|2349-2354|共6页
  • 作者单位

    Section of Neurobiology, Biomedicine, Department of Health Science and Technology, Aalborg University, Aalborg,DK-9220, Denmark;

    Section of Neurobiology, Biomedicine, Department of Health Science and Technology, Aalborg University, Aalborg,DK-9220, Denmark;

    Section of Neurobiology, Biomedicine, Department of Health Science and Technology, Aalborg University, Aalborg,DK-9220, Denmark;

    Section of Neurobiology, Biomedicine, Department of Health Science and Technology, Aalborg University, Aalborg,DK-9220, Denmark;

    Section of Neurobiology, Biomedicine, Department of Health Science and Technology, Aalborg University, Aalborg,DK-9220, Denmark;

    Section of Neurobiology, Biomedicine, Department of Health Science and Technology, Aalborg University, Aalborg,DK-9220, Denmark;

    Section of Neurobiology, Bio-medicine, Department of Health Science and Technology, Fr. Bajers Vej3B, 1.216, Aalborg University, DK-9220 Aalborg East, Denmark;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    blood-brain barrier; endothelium; gene therapy; magnetic nanoparticle; transferrin; transport;

    机译:血脑屏障;内皮基因治疗;磁性纳米粒子转铁蛋白运输;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号